Treatment of hepatitis C genotypes 1 to 5 in sub-saharan Africa using direct-acting antivirals

Amir Sultan, Abate Bane, Grace Braimoh, Jose D. Debes

Research output: Contribution to journalArticlepeer-review

Abstract

There is limited knowledge of the use of direct acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) in sub-Saharan Africa. We prospectively evaluated individuals infected with HCV genotypes 1 to 5 in Addis Ababa, Ethiopia. Liver fibrosis was assessed by AST-platelet ratio index score and cirrhosis by imaging and laboratory values. All 164 individuals completed treatment. The majority of patients had genotype 4 (76%), and 19% of participants showed evidence of cirrhosis. Sustained virologic response (SVR) across all genotypes was 98.8%. In those with cirrhosis, SVR was 93.5% and in non-cirrhotics 100%. Our study demonstrates broad genotype successful treatment of HCV with DAAs in sub-Saharan Africa, demonstrating the feasibility of HCV elimination in resource-limited settings.

Original languageEnglish (US)
Pages (from-to)2083-2084
Number of pages2
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume103
Issue number5
DOIs
StatePublished - Nov 2020

Bibliographical note

Funding Information:
Financial support: This study was supported by Harold Amos Medical Faculty Development Award (AMFDP), NIH-NCI R21 CA215883-01A1, and University of Minnesota Center for Global Health and Social Responsibility Global Health Seed Award to J. D. D.

Publisher Copyright:
Copyright © 2020 by The American Society of Tropical Medicine and Hygiene

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint

Dive into the research topics of 'Treatment of hepatitis C genotypes 1 to 5 in sub-saharan Africa using direct-acting antivirals'. Together they form a unique fingerprint.

Cite this